Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707
Pfizer is paying $1.25 billion upfront and up to $4.8 billion in milestone payments in a licensing deal with Chinese biotech 3SBio, securing exclusive global rights (excluding China) to the bispecific antibody SSGJ-707, targeting PD-1 and VEGF pathways234.
The total potential value of the agreement is over $6 billion, with Pfizer also committing to double-digit tiered royalties if SSGJ-707 is approved and commercialized outside China24.
SSGJ-707 has shown strong early results in phase II clinical trials for non-small cell lung cancer (NSCLC), reporting up to 81.3% overall response rate and a 100% disease control rate, with promising outcomes in metastatic colorectal and gynecologic cancers as well1.
The asset has recently received clearance in China for a phase III study in lung cancer and is set to begin late-stage development this year23.
This move places Pfizer among a growing number of companies investing in PD-1/VEGF bispecifics, a class of cancer immunotherapies rapidly gaining momentum globally following recent successes by companies like Akeso and Summit Therapeutics13.
The deal is expected to close in the third quarter of 2025, pending regulatory and shareholder approvals23.
Sources:
1. https://www.pharmexec.com/view/pfizer-3sbio-forge-licensing-pact-ssgj-707-target-lung-colorectal-gynecologic-cancers
2. https://www.bioworld.com/articles/720339-pfizer-bets-6b-on-3sbios-bispecific-pd-1-vegf-antibody
3. https://www.biospace.com/business/pfizer-puts-6b-on-the-line-for-3sbios-pd-1-vegf-antibody